secwatch.observer — SEC 8-K summary
======================================

Issuer:     PMV Pharmaceuticals, Inc. (PMVP)
CIK:        0001699382
Form:       8-K
Filed at:   2022-01-06T23:59:59+00:00
Accession:  0001193125-22-003158
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PMV Pharma appoints Kirsten Flowers to Board; Dr. Peter Thompson resigns
------------------------------------------------------------------------

- Dr. Peter Thompson resigned from the board and committees effective January 5, 2022; not related to any disagreement.
- Kirsten Flowers appointed Class I director effective January 5, 2022, filling the vacancy until the 2024 annual meeting.
- Ms. Flowers is Chief Commercial Officer of Kura Oncology, with prior roles at Array Biopharma and Pfizer.
- Her compensation follows the Company's Outside Director Compensation Policy; an indemnification agreement was executed.
- No arrangements or family relationships exist between Ms. Flowers and any other director or officer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1699382/000119312522003158/0001193125-22-003158-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1699382/000119312522003158/d86525d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-003158

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer